{"id":"W1982688102","doi":"10.1038/sj.gt.3302802","title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment","year":2006,"lang":"en","type":"article","venue":"Gene Therapy","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":283,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Manitoba Health; Hôpital du Sacré-Cœur de Montréal; Vancouver Hospital and Health Sciences Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Victoria Heart Institute Foundation; University of Alberta Hospital; Montreal Heart Institute; Alberta Hospital Edmonton; Foothills Medical Centre; Royal Victoria Hospital; Women's College Hospital; Hôpital Notre-Dame; London Health Sciences Centre","funders":"","keywords":"Angina; Medicine; Revascularization; Genetic enhancement; Canadian Cardiovascular Society; Clinical endpoint; Coronary artery disease; Cardiology; Randomized controlled trial; Internal medicine; Therapeutic angiogenesis; Perfusion; Adverse effect; Surgery; Angiogenesis; Neovascularization; Myocardial infarction; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197263,0.002386402,0.004826242,0.000662644,0.00050025,0.001377092,0.001164674,0.002259403,0.00536986],"category_scores_gemma":[0.001765728,0.0008629346,0.001704231,0.0007136379,0.001920062,0.001504648,0.0004501235,0.003930284,0.0006923935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008858902,"about_ca_system_score_gemma":0.001083446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001030881,"about_ca_topic_score_gemma":0.001722566,"domain_scores_codex":[0.9991479,0.0004514591,0.00003766889,0.0001361613,0.00005419232,0.0001726417],"domain_scores_gemma":[0.9991326,0.0003286208,0.0001531254,0.00006644083,0.00003474936,0.0002844244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823132,0.005777533,0.0002408774,0.0002155678,0.0003576898,0.00002073913,0.00002589762,0.0002615657,0.00214689,0.00008603922,0.0003237705,0.008230177],"study_design_scores_gemma":[0.9581463,0.04031275,0.0004866728,0.000007987517,0.0001956604,0.00001165255,0.000009127853,0.0002477192,0.0003073747,0.00007609915,0.0001905485,0.000008099224],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899737,0.003664999,0.0009321522,0.000846443,0.0005631394,0.001875364,0.0006145352,0.0001257183,0.001404052],"genre_scores_gemma":[0.9879802,0.002253935,0.001810148,0.0009368054,0.0007740015,0.003066483,0.0007432799,0.00003703865,0.002398176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00536986,"threshold_uncertainty_score":0.01796401,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008016024261516347,"score_gpt":0.2603112171652076,"score_spread":0.2522951929036913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}